Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
genleukocel-t
- Development stage
- Phase 1
- Lead developer
- Immusoft
- Modality
- Cell Therapies, Gene Therapies
- Administration
- Intravenous
01
Overview
Genleukocel-t is a cell therapy developed by Immusoft Corporation. Its lead candidate, iduronicrin genleukocel-T (also known as ISP-001), leverages Immusoft's proprietary Immune System Programming (ISP™) platform to modify B cells. These modified B cells are designed to produce iduronicrin (alpha-L-iduronidase), an enzyme deficient in patients with Mucopolysaccharidosis type I (MPS I). The drug is currently in Phase I/II clinical development for MPS I, aiming to provide enzyme replacement therapy.
- Other names
- iduronicrin genleukocel-T
Beyond the preview
Go deeper on genleukocel-t.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on genleukocel-t.